XML 17 R5.htm IDEA: XBRL DOCUMENT v3.26.1
Condensed Consolidated Statement of Changes in Stockholders’ Equity - Unaudited - USD ($)
$ in Thousands
Total
Class A Common Stock
Class B Common Stock
Total vTv Therapeutics Inc Stockholders’ Equity (Deficit)
Common Stock
Class A Common Stock
Common Stock
Class B Common Stock
Additional Paid-in Capital
Accumulated Deficit
Noncontrolling Interest
Beginning balance, shares (in shares) at Dec. 31, 2024         2,612,257 577,349      
Beginning balance at Dec. 31, 2024 $ 14,301     $ 12,199 $ 26 $ 6 $ 311,885 $ (299,718) $ 2,102
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Net income (loss) attributable to vTv Therapeutics Inc. (11,138)     (11,138)       (11,138)  
Issuance of common stock upon exercise of stock options (in shares)         700        
Issuance of common stock upon exercise of stock options 9     9     9 0  
Net shares withheld for tax withholding related to the settlement of equity awards (in shares)         4,258        
Net shares withheld for tax withholding related to the settlement of equity awards. (51)     (51)     (51)   0
Share-based compensation 1,743     1,743     1,743    
Net loss attributable to noncontrolling interest (2,459)               (2,459)
Ending balance, shares (in shares) at Jun. 30, 2025         2,617,215 577,349      
Ending balance at Jun. 30, 2025 2,405     2,762 $ 26 $ 6 313,586 (310,856) (357)
Beginning balance, shares (in shares) at Mar. 31, 2025         2,612,257 577,349      
Beginning balance at Mar. 31, 2025 8,897     7,920 $ 26 $ 6 312,698 (304,810) 977
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Net income (loss) attributable to vTv Therapeutics Inc. (6,046)     (6,046)       (6,046)  
Issuance of common stock upon exercise of stock options (in shares)         700        
Issuance of common stock upon exercise of stock options 9     9     9    
Net shares withheld for tax withholding related to the settlement of equity awards (in shares)         4,258        
Net shares withheld for tax withholding related to the settlement of equity awards. (51)     (51)     (51)    
Share-based compensation 930     930     930    
Net loss attributable to noncontrolling interest (1,334)               (1,334)
Ending balance, shares (in shares) at Jun. 30, 2025         2,617,215 577,349      
Ending balance at Jun. 30, 2025 2,405     2,762 $ 26 $ 6 313,586 (310,856) $ (357)
Beginning balance, shares (in shares) at Dec. 31, 2025   3,938,654 241   3,938,654 241      
Beginning balance at Dec. 31, 2025       64,437 $ 39 $ 0 391,090 (326,692)  
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Net income (loss) attributable to vTv Therapeutics Inc. 11,080     11,080       11,080  
Share-based compensation       3,115     3,115    
Conversion of Class B common stock to Class A common stock (in shares)         149 (149)      
Net loss attributable to noncontrolling interest 0                
Ending balance, shares (in shares) at Jun. 30, 2026   3,938,803 92   3,938,803 92      
Ending balance at Jun. 30, 2026       78,632 $ 39 $ 0 394,205 (315,612)  
Beginning balance, shares (in shares) at Mar. 31, 2026         3,938,654 241      
Beginning balance at Mar. 31, 2026       89,959 $ 39 $ 0 392,478 (302,558)  
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Net income (loss) attributable to vTv Therapeutics Inc. (13,054)     (13,054)       (13,054)  
Share-based compensation       1,727     1,727    
Conversion of Class B common stock to Class A common stock (in shares)         149 (149)      
Net loss attributable to noncontrolling interest $ 0                
Ending balance, shares (in shares) at Jun. 30, 2026   3,938,803 92   3,938,803 92      
Ending balance at Jun. 30, 2026       $ 78,632 $ 39 $ 0 $ 394,205 $ (315,612)